Cargando…

Therapeutic Strategies in the Management of COVID-19

Since December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Naik, Rajashri R., Shakya, Ashok K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890447/
https://www.ncbi.nlm.nih.gov/pubmed/33614709
http://dx.doi.org/10.3389/fmolb.2020.636738
_version_ 1783652515871457280
author Naik, Rajashri R.
Shakya, Ashok K.
author_facet Naik, Rajashri R.
Shakya, Ashok K.
author_sort Naik, Rajashri R.
collection PubMed
description Since December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 are trying to content the virus by isolating the patients and treating them with the approved antiviral that have been previously used in treating SARS, MERS, and drugs that are used to treat other viral infections. Some of these are under clinical trials. At present there are no therapeutically effective antiviral present and there are no vaccines or drugs available that are clinically approved for treating the corona virus. The current strategy is to re-purpose the available drugs or antiviral that can minimise or reduce the burden of the health care emergencies. In this article the reuse of antiviral, US-FDA approved drugs, plant based therapeutic, anti-malarial, anti-parasitic, anti–HIV drugs and the traditional medicines that are being currently used in treating the symptoms of COVID–19 patients is discussed emphasis is also given on the treatment using monoclonal antibodies. The present article provides the therapeutic strategies that will qualify as one of the best available treatment for the better management of the COVID–19 patients in order to achieve medical benefits.
format Online
Article
Text
id pubmed-7890447
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78904472021-02-19 Therapeutic Strategies in the Management of COVID-19 Naik, Rajashri R. Shakya, Ashok K. Front Mol Biosci Molecular Biosciences Since December 2019, SARS-CoV-2 (COVID-19), novel corona virus has caused pandemic globally, with rise in the number of cases and death of the patients. Vast majority of the countries that are dealing with rise in the active cases and death of patients suffering from novel corona viruses COVID-19 are trying to content the virus by isolating the patients and treating them with the approved antiviral that have been previously used in treating SARS, MERS, and drugs that are used to treat other viral infections. Some of these are under clinical trials. At present there are no therapeutically effective antiviral present and there are no vaccines or drugs available that are clinically approved for treating the corona virus. The current strategy is to re-purpose the available drugs or antiviral that can minimise or reduce the burden of the health care emergencies. In this article the reuse of antiviral, US-FDA approved drugs, plant based therapeutic, anti-malarial, anti-parasitic, anti–HIV drugs and the traditional medicines that are being currently used in treating the symptoms of COVID–19 patients is discussed emphasis is also given on the treatment using monoclonal antibodies. The present article provides the therapeutic strategies that will qualify as one of the best available treatment for the better management of the COVID–19 patients in order to achieve medical benefits. Frontiers Media S.A. 2021-02-04 /pmc/articles/PMC7890447/ /pubmed/33614709 http://dx.doi.org/10.3389/fmolb.2020.636738 Text en Copyright © 2021 Naik and Shakya. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (http://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Naik, Rajashri R.
Shakya, Ashok K.
Therapeutic Strategies in the Management of COVID-19
title Therapeutic Strategies in the Management of COVID-19
title_full Therapeutic Strategies in the Management of COVID-19
title_fullStr Therapeutic Strategies in the Management of COVID-19
title_full_unstemmed Therapeutic Strategies in the Management of COVID-19
title_short Therapeutic Strategies in the Management of COVID-19
title_sort therapeutic strategies in the management of covid-19
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890447/
https://www.ncbi.nlm.nih.gov/pubmed/33614709
http://dx.doi.org/10.3389/fmolb.2020.636738
work_keys_str_mv AT naikrajashrir therapeuticstrategiesinthemanagementofcovid19
AT shakyaashokk therapeuticstrategiesinthemanagementofcovid19